Trial Profile
Phase IIb study of sapacitabine in older patients with myelodysplastic syndrome who have failed prior hypomethylating agent therapy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2016
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Cyclacel Pharmaceuticals
- 11 Jan 2016 As per a Cyclacel media release, the company expects to start this trial in 2016.
- 11 Nov 2014 New trial record